Share This Article:

Anticardiolipin antibodies do not mediate macrovascular complications of type 2 diabetes

Abstract Full-Text HTML Download Download as PDF (Size:43KB) PP. 37-39
DOI: 10.4236/ojim.2012.21009    2,896 Downloads   4,872 Views  

ABSTRACT

The relationship of anticardiolipin antibodies (ACA), markers of the antiphospholipid syndrome, with vascular complications of diabetes mellitus is polemic. This cross-sectional study assessed the frequency of IgG, IgM, and IgA ACA in type 2 diabetics with and without history of vascular events for the last 5 years, and in healthy controls. ACA were detected by enzyme immunoassay. A total of 73 type 2 diabetics (33 with history of vascular events) and 54 healthy controls were tested. Most diabetics were female (p = 0.003), and older than controls (p < 0.001). Mean duration of disease was 10 years. The prevalence of a positive ACA test was 7.4% in controls and 9.5% in diabetics (p = 0.910). Comparison of healthy controls and diabetics with and without history of macrovasculopathy, after adjusting for gender and age, showed no significant differences as to the presence of ACA (p > 0.09). ACA positivity rates were also similar when diabetics with and without history of vasculopathy were compared (p > 0.47). After adjusting for gender, age, hypertension, and smoking status, a weak but statistically insignificant association between IgM ACA and diabetics with vasculopathy was found (adjusted OR 2.7; 95% CI 0.2 - 34.2; p = 0.441). Overall, levels of IgG (r = 0.25; p = 0.005) and IgM (r = 0.23; p = 0.010) ACA were associated with increasing age. In short, the frequency of a positive ACA test in type 2 diabetics (with or without previous macrovasculopathy) was not significant as compared to healthy controls. There was no association of ACA with vascular events in patients with type 2 diabetes.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Copetti, C. , Perreynoud, M. , Bisi, M. and Staub, H. (2012) Anticardiolipin antibodies do not mediate macrovascular complications of type 2 diabetes. Open Journal of Internal Medicine, 2, 37-39. doi: 10.4236/ojim.2012.21009.

References

[1] Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4, 295-306. doi:10.1111/j.1538-7836.2006.01753.x
[2] Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., et al. (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiology in Review, 13, 322-327.
[3] Gharavi, A.E., Harris, E.N., Asherson, R.A. and Hughes, G.R. (1987) Anticardiolipin antibodies: Isotype distribution and phospholipid specificity. Annals of the Rheumatic Diseases, 46, 1-6. doi:10.1136/ard.46.1.1
[4] Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr., et al. (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. Journal of the American Medical Association, 289, 2560-2572. doi:10.1001/jama.289.19.2560
[5] Filozof, C., Fernandez Pinilla, M.C. and Fernández-Cruz, A. (2004) Smoking cessation and weight gain. Obesity Research, 5, 95-103. doi:10.1111/j.1467-789X.2004.00131.x
[6] King, H., Aubert, R.E. and Herman, W.H. (1998) Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care, 21, 1414-1431. doi:10.2337/diacare.21.9.1414
[7] Kannel, W.B. and McGee, D.L. (1979) Diabetes and cardiovascular disease. The Framingham study. Journal of the American Medical Association, 241, 2035-2038. doi:10.1001/jama.1979.03290450033020
[8] Ciarla, M.V., Bocciarelli, A., Di Gregorio, S., Tordi, A., Cotroneo, P., Marra, G., et al. (2001) Autoantibodies and endothelial dysfunction in well-controlled, uncomplicated insulin-dependent diabetes mellitus patients. Atherosclerosis, 158, 241-246. doi:10.1016/S0021-9150(01)00440-3
[9] Staub, H.L., Norman, G.L., Crowther, T., Da Cunha, V.R., Polanczyk, A., Bohn, J.M., et al. (2003) Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arquivos De Neuro-Psiquitria, 61, 757-763. doi:10.1590/S0004-282X2003000500010
[10] Ranzolin, A., Bohn, J.M., Norman, G.L., Manenti, E., Bodanese, L.C., Von Muhlen, C.A., et al. (2004) Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arquivos Brasileiros de Cardiologia, 83, 141-144.
[11] Recuero, M.L., Silva, J.B., Norman, G.L., Von Muhlen, C.A. and Staub, H.L. (2007) IgA antibodies to beta2-glycoprotein I and carotid disease. Israel Medical Association Journal, 9, 495-496.
[12] Franck, M., Staub, H.L., Petracco, J.B., Norman, G.L., Lassen, A.J., Schiavo, N., et al. (2007) Autoantibodies to the atheroma component beta2-glycoprotein I and risk of symptomatic peripheral artery disease. Angiology, 58, 295-302. doi:10.1177/0003319707302493
[13] Krás Borges, R., Bodanese, L., Von Mühlen, C., Repetto, G., Viehe, M., Norman, G., et al. (2011) Anti-beta2-glycoprotein I autoantibodies and metabolic syndrome. Arquivos Brasileiros de Cardiologia, 96, 272-276.
[14] Hendra, T.J., Baguley, E., Harris, E.N., Khamashta, M.H., Trembath, R.C., Hughes, G.R., et al. (1989) Anticardiolipin antibody levels in diabetic subjects with and without coronary artery disease. Postgraduate Medical Journal, 65, 140-143. doi:10.1136/pgmj.65.761.140
[15] Gargiulo, P., Goldberg, J., Romani, B., Schiaffini, R., Ciampalini, P., Faulk, W.P., et al. (1999) Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus. Clinical & Experimental Immunology, 118, 30-34. doi:10.1046/j.1365-2249.1999.01014.x
[16] Galtier-Dereure, F., Biron, C., Vies, M., Bourgeois, V., Schved, J.F. and Bringer, J. (1998) Vascular complications of diabetes mellitus: What role for phospholipid-binding antibodies? Lupus, 7, 469-474. doi:10.1191/096120398678920488
[17] Triolo, G., Giardina, E., Scarantino, G., Seddio, G. and Bompiani, G. (1989) Detection of anti-phospholipid (cardiolipin, phosphatidylserine) antibodies in the serum of patients with non insulin-dependent (type 2) diabetes mellitus and macroangiopathy. Coexistence of antiplatelet reactivity. Diabetes Research, 10, 63-67.
[18] Fields, R.A., Toubbeh, H., Searles, R.P. and Bankhurst, A.D. (1989) The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. Journal of Rheumatology, 16, 623-625.
[19] Chakravarty, K.K., Gray, R.E., Webley, M., Byron, M.A. and Wozniak, J. (1991) Prevalence of anticardiolipin antibodies in the elderly British population. Postgraduate Medical Journal, 67, 358-361. doi:10.1136/pgmj.67.786.358
[20] Tarkun, I., Hacihanefioglu, A., Tarkun, P., Cetinarslan, B. and Canturk, Z. (2005) Anticardiolipin and anti-beta2 glycoprotein I antibody concentrations in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 68, 181-187. doi:10.1016/j.diabres.2004.09.005

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.